BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis. Polaris Partners led the seed...
BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death. RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

Ervaxx Ltd. emerged from stealth on Tuesday with £13 million ($16.8 million) from SV Health Investors and a platform for discovering and validating a new type of neoantigen present in the dark matter of the...
BioCentury | Sep 25, 2019
Targets & Mechanisms

Switching targets to avoid resistance to CAR Ts

City of Hope researchers have engineered CAR T cells directed against a new B cell target that could overcome resistance to or replace canonical CAR Ts. The novel CAR T therapy against TNFRSF13c, which was...
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets....
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
BioCentury | Jan 11, 2019
Company News

Trigr gets rights to ABL's bispecific antibody

ABL Bio Inc. (KOSDAQ:298380) granted Trigr Therapeutics Inc. (Irvine, Calif.) exclusive rights to TR009 (formerly ABL001, NOV1501), a bispecific antibody targeting δ like canonical Notch ligand 4 (DLL4) and VEGF. Trigr gets worldwide development and...
BioCentury | Jan 11, 2019
Company News

AbbVie records $4B impairment on Stemcentrx deal

As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Jan. 4 it...
Items per page:
1 - 10 of 72
BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis. Polaris Partners led the seed...
BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death. RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

Ervaxx Ltd. emerged from stealth on Tuesday with £13 million ($16.8 million) from SV Health Investors and a platform for discovering and validating a new type of neoantigen present in the dark matter of the...
BioCentury | Sep 25, 2019
Targets & Mechanisms

Switching targets to avoid resistance to CAR Ts

City of Hope researchers have engineered CAR T cells directed against a new B cell target that could overcome resistance to or replace canonical CAR Ts. The novel CAR T therapy against TNFRSF13c, which was...
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets....
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
BioCentury | Jan 11, 2019
Company News

Trigr gets rights to ABL's bispecific antibody

ABL Bio Inc. (KOSDAQ:298380) granted Trigr Therapeutics Inc. (Irvine, Calif.) exclusive rights to TR009 (formerly ABL001, NOV1501), a bispecific antibody targeting δ like canonical Notch ligand 4 (DLL4) and VEGF. Trigr gets worldwide development and...
BioCentury | Jan 11, 2019
Company News

AbbVie records $4B impairment on Stemcentrx deal

As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Jan. 4 it...
Items per page:
1 - 10 of 72